Biotransformation pathway maps in WikiPathways enable direct visualization of drug metabolism related expression changes

Drug Discovery Today

Volumn 15, Issue 19-20, 2010, Pages 851-858

  Jennen, Danyel G J ^a   Gaj, Stan ^a   Giesbertz, Pieter J ^a   van Delft, Joost H M ^a   Evelo, Chris T ^a   Kleinjans, Jos C S ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

BIOTRANSFORMATION; DRUG METABOLISM; DRUG TRANSFORMATION; FUNCTIONAL GENOMICS; HUMAN; INTERNET; MICROARRAY ANALYSIS; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; REVIEW; XENOBIOTIC METABOLISM;

BIOTRANSFORMATION; DATABASES, FACTUAL; HUMANS; LIVER; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; SOFTWARE;

EID: 77957684689     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.08.002     Document Type: Review

References (55)

1. Testa B. Drug metabolism for the perplexed medicinal chemist. Chem. Biodivers. 2009, 6:2055-2070.
2. Yengi L.G., et al. The evolving role of drug metabolism in drug discovery and development. Pharm. Res. 2007, 24:842-858.
3. Natsoulis G., et al. The liver pharmacological and xenobiotic gene response repertoire. Mol. Syst. Biol. 2008, 4:175.
4. Bolt H.M., Hengstler J.G. Predicting drug metabolism-dependent toxicity. Arch. Toxicol. 2009, 83:635-638.
5. Decker M., et al. Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch. Toxicol. 2009, 83:297-318.
6. Pelkonen O., et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 2008, 82:667-715.
7. Guguen-Guillouzo C., et al. Stem cell-derived hepatocytes and their use in toxicology. Toxicology 2010, 270:3-9.
8. Brolen G., et al. Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. J. Biotechnol. 2010, 145:284-294.
9. Si-Tayeb K., et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010, 51:297-305.
10. Coecke S., et al. Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Altern. Lab. Anim. 2006, 34:49-84.
11. Cashman J.R., Zhang J. Human flavin-containing monooxygenases. Annu. Rev. Pharmacol. Toxicol. 2006, 46:65-100.
12. Coughtrie M.W. Sulfation through the looking glass-recent advances in sulfotransferase research for the curious. Pharmacogenomics J. 2002, 2:297-308.
13. Guengerich F.P. Cytochrome p450 and chemical toxicology. Chem. Res. Toxicol. 2008, 21:70-83.
14. Meyer U.A. Polymorphism of human acetyltransferases. Environ. Health Perspect. 1994, 102(Suppl. 6):213-216.
15. Testa B., Kramer S.D. The biochemistry of drug metabolism-an introduction: part 4. Reactions of conjugation and their enzymes. Chem. Biodivers. 2008, 5:2171-2336.
16. Wixon J., Kell D. The Kyoto encyclopedia of genes and genomes-KEGG. Yeast 2000, 17:48-55.
17. Matthews L., et al. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res. 2009, 37:D619-D622.
18. van Iersel M.P., et al. Presenting and exploring biological pathways with PathVisio. BMC Bioinform. 2008, 9:399.
19. Pico A.R., et al. WikiPathways: pathway editing for the people. PLoS Biol. 2008, 6:e184.
20. Giesbertz P., et al. Application of WikiPathways and PathVisio for pathway interpretation of toxicogenomics data. Book of Abstracts Benelux Bioinformatics Conference (BBC-09) 2009.
21. Testa B., Kramer S.D. The biochemistry of drug metabolism-an introduction: part 1. Principles and overview. Chem. Biodivers. 2006, 3:1053-1101.
22. Liska D.J. The detoxification enzyme systems. Altern. Med. Rev. 1998, 3:187-198.
23. Bader G.D., et al. Pathguide: a pathway resource list. Nucleic Acids Res. 2006, 34:D504-D506.
24. Frolkis A., et al. SMPDB: The Small Molecule Pathway Database. Nucleic Acids Res. 2010, 38:D480-D487.
25. Caspi R., et al. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res. 2010, 38:D473-D479.
26. Hebels D.G., et al. Molecular signatures of N-nitroso compounds in Caco-2 cells: implications for colon carcinogenesis. Toxicol. Sci. 2009, 108:290-300.
27. van Iersel M.P., et al. The BridgeDb framework: standardized access to gene, protein and metabolite identifier mapping services. BMC Bioinform. 2010, 11:5.
28. Safran M., et al. GeneCards 2002: towards a complete, object-oriented, human gene compendium. Bioinformatics 2002, 18:1542-1543.
29. Chang A., et al. BRENDA, AMENDA and FRENDA the enzyme information system: new content and tools in 2009. Nucleic Acids Res. 2009, 37:D588-D592.
30. Salomonis N., et al. GenMAPP 2: new features and resources for pathway analysis. BMC Bioinform. 2007, 8:217.
31. Hubbard T.J., et al. Ensembl 2009. Nucleic Acids Res. 2009, 37:D690-D697.
32. Sayers E.W., et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2009, 37:D5-D15.
33. Parkinson H., et al. ArrayExpress update-from an archive of functional genomics experiments to the atlas of gene expression. Nucleic Acids Res. 2009, 37:D868-D872.
34. Roth R.B., et al. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 2006, 7:67-80.
35. Reymann S., Borlak J. Topoisomerase II inhibition involves characteristic chromosomal expression patterns. BMC Genomics 2008, 9:324.
36. Shi L., et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 2006, 24:1151-1161.
37. Jennen D.G., et al. Comparison of HepG2 and HepaRG by whole genome gene expression analysis for the purpose of chemical hazard identification. Toxicol. Sci. 2010, 115:66-79.
38. Dai M., et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005, 33:e175.
39. Irizarry R.A., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
40. De Groot P.J., et al. NuGO contributions to GenePattern. Genes Nutr. 2008, 3:143-146.
41. Benedetti M.S., et al. Drug metabolism and pharmacokinetics. Drug Metab. Rev. 2009, 41:344-390.
42. Higgins J.P., et al. Gene expression in the normal adult human kidney assessed by complementary DNA microarray. Mol. Biol. Cell 2004, 15:649-656.
43. Wu C., et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009, 10:R130.
44. Su A.I., et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:6062-6067.
45. Castell J.V., et al. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin. Drug Metab. Toxicol. 2006, 2:183-212.
46. Hsu I.C., et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 1993, 14:987-992.
47. Knasmuller S., et al. Use of metabolically competent human hepatoma cells for the detection of mutagens and antimutagens. Mutat. Res. 1998, 402:185-202.
48. Wilkening S., et al. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab. Dispos. 2003, 31:1035-1042.
49. Guillouzo A., et al. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 2007, 168:66-73.
50. Kanebratt K.P., Andersson T.B. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab. Dispos. 2008, 36:137-145.
51. Harris A.J., et al. Comparison of basal gene expression profiles and effects of hepatocarcinogens on gene expression in cultured primary human hepatocytes and HepG2 cells. Mutat. Res. 2004, 549:79-99.
52. Kanebratt K.P., Andersson T.B. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab. Dispos. 2008, 36:1444-1452.
53. Liguori M.J., et al. Trovafloxacin-induced gene expression changes in liver-derived in vitro systems: comparison of primary human hepatocytes to HepG2 cells. Drug Metab. Dispos. 2008, 36:223-233.
54. Olsavsky K.M., et al. Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol. Appl. Pharmacol. 2007, 222:42-56.
55. Turpeinen M., et al. Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. Toxicol. In Vitro 2009, 23:748-753.